Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce cardiovascular events in patients with ACS. However, there is substantial inter-individual variability in the response to clopidogrel treatment, in addition to prolonged recovery of platelet reactivity as a result of irreversible binding to P2Y12 receptors. This high inter-individual variability in treatment response has primarily been associated with genetic polymorphisms in the genes encoding for cytochrome (CYP) 2C19, which affect the pharmacokinetics of clopidogrel. While the US Food and Drug Administration has issued a boxed warning for CYP2C19 poor metabolizers because of potentially reduced efficacy in these patients, results from multivariate analyses suggest that additional factors, including age, sex, obesity, concurrent diseases and drug–drug interactions, may all contribute to the overall between-subject variability in treatment response. However, the extent to which each of these factors contributes to the overall variability, and how they are interrelated, is currently unclear. The objective of this review article is to provide a comprehensive update on the different factors that influence the pharmacokinetics and pharmacodynamics of clopidogrel and how they mechanistically contribute to inter-individual differences in the response to clopidogrel treatment.

[1]  Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. , 2003 .

[2]  I. Zineh,et al.  Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers , 2014, Journal of clinical pharmacology.

[3]  A. Kastrati,et al.  No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting , 2012, Circulation. Cardiovascular interventions.

[4]  A. Kastrati,et al.  Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.

[5]  Alan R. Shuldiner,et al.  Pharmacogenomics of Anti-platelet Therapy: How much evidence is enough for clinical implementation? , 2013, Journal of Human Genetics.

[6]  Y. Daali,et al.  Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis , 2012, Journal of thrombosis and haemostasis : JTH.

[7]  Deepak L. Bhatt,et al.  Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[8]  Masato Ohbuchi,et al.  Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4 , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  O. Hess,et al.  Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. , 2007, The American journal of cardiology.

[10]  Jia Su,et al.  ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis , 2012, PloS one.

[11]  S. Scott,et al.  Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. , 2011, JAMA.

[12]  Ute Hofmann,et al.  Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes , 2010, Drug Metabolism and Disposition.

[13]  Jane A. Linderbaum,et al.  2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  Z. Motovska,et al.  Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking “Paradox” , 2009, Journal of cardiovascular pharmacology.

[15]  K. Winters,et al.  Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel , 2010, Clinical pharmacokinetics.

[16]  D. Gurwitz,et al.  Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. , 2012, Journal of affective disorders.

[17]  N. Kleiman,et al.  Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. , 2007, Thrombosis research.

[18]  Deepak L. Bhatt,et al.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. , 2010, The New England journal of medicine.

[19]  D. Angiolillo,et al.  Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[20]  Masafumi Ueno,et al.  Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. , 2012, JACC. Cardiovascular interventions.

[21]  S. Kaul,et al.  Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease , 2007, Annals of Internal Medicine.

[22]  J. O’Connell,et al.  The CYP2C19*17 variant is not independently associated with clopidogrel response , 2013, Journal of thrombosis and haemostasis : JTH.

[23]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[24]  Osamu Okazaki,et al.  Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.

[25]  P. Hollenberg,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyl Residue 475 and Loss of Heme , 2011, Molecular Pharmacology.

[26]  J. Suh,et al.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel , 2006, Canadian Medical Association Journal.

[27]  R. Califf,et al.  The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.

[28]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[29]  N. Lakkis,et al.  Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. , 2011, Journal of the American College of Cardiology.

[30]  J. Mega,et al.  Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. , 2014, Journal of the American College of Cardiology.

[31]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[32]  S. Laporte,et al.  Investigation of drug–drug interactions between clopidogrel and fluoxetine , 2013, Fundamental & clinical pharmacology.

[33]  Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR , 2012, European Journal of Clinical Pharmacology.

[34]  B. Giusti,et al.  Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients , 2007, Pharmacogenetics and genomics.

[35]  Nikki M. Carroll,et al.  Delays in Filling Clopidogrel Prescription After Hospital Discharge and Adverse Outcomes After Drug-Eluting Stent Implantation: Implications for Transitions of Care , 2010, Circulation. Cardiovascular quality and outcomes.

[36]  Jiaoxing Li,et al.  ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. , 2012, Thrombosis research.

[37]  A. Kastrati,et al.  Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. , 2010, European heart journal.

[38]  K. Winters,et al.  Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. , 2012, British journal of clinical pharmacology.

[39]  D. Angiolillo,et al.  Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[40]  C. Cannon,et al.  High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. , 2008, American heart journal.

[41]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[42]  J. Stanslas,et al.  Genetic Polymorphisms and Drug Interactions Leading to Clopidogrel Resistance: Why the Asian Population Requires Special Attention , 2013, The International journal of neuroscience.

[43]  G. Patti,et al.  Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. , 2013, Journal of the American College of Cardiology.

[44]  S. Yusuf,et al.  Renal function and outcomes in acute coronary syndrome: impact of clopidogrel , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[45]  M. Gawaz,et al.  CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. , 2008, Pharmacogenomics.

[46]  H. Bøtker,et al.  Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events , 2012, European journal of clinical investigation.

[47]  A. Kastrati,et al.  High platelet reactivity and clinical outcome – Fact and fiction , 2011, Thrombosis and Haemostasis.

[48]  L. Bergougnan,et al.  Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies , 2011, Clinical pharmacology and therapeutics.

[49]  Masafumi Ueno,et al.  Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus , 2013, Journal of Thrombosis and Thrombolysis.

[50]  O. Klungel,et al.  The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response , 2010, Thrombosis and Haemostasis.

[51]  Tomomi Kimura,et al.  A Single Nucleotide Polymorphism in the Carboxylesterase Gene Is Associated with the Responsiveness to Imidapril Medication and the Promoter Activity , 2005, Hypertension Research.

[52]  P. Gurbel,et al.  Clopidogrel resistance? , 2007, Thrombosis research.

[53]  V. Bongard,et al.  Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levels , 2011, Thrombosis and Haemostasis.

[54]  J. W. Davis,et al.  Adenosine diphosphate-induced platelet aggregation of hospitalized men. , 2009, Scandinavian journal of haematology.

[55]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[56]  A. Zwinderman,et al.  Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions , 2008, Human mutation.

[57]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[58]  I. Xanthopoulou,et al.  CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. , 2012, Thrombosis research.

[59]  Si‐Hyuck Kang,et al.  Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability but Is Associated with Clinical Outcome after PCI , 2013, PloS one.

[60]  J. Skinner,et al.  Clopidogrel Use and Early Outcomes Among Older Patients Receiving a Drug-Eluting Coronary Artery Stent , 2012, Circulation. Cardiovascular quality and outcomes.

[61]  Dick M. Goedhart,et al.  The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). , 2010, The American journal of cardiology.

[62]  V. Ribeiro,et al.  Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel–PPIs drug interaction , 2011, European journal of gastroenterology & hepatology.

[63]  M. Fromm,et al.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. , 2010, Journal of the American College of Cardiology.

[64]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[65]  A. Kastrati,et al.  Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. , 2008, European heart journal.

[66]  K. Winters,et al.  Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects , 2008, Pharmacotherapy.

[67]  I. Olkin,et al.  Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature , 2012, Digestive Diseases and Sciences.

[68]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[69]  K. Winters,et al.  Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently , 2007, Clinical pharmacology and therapeutics.

[70]  S. James,et al.  Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients , 2013, Journal of Thrombosis and Thrombolysis.

[71]  Si‐Hyuck Kang,et al.  Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. , 2013, International journal of cardiology.

[72]  G. Andersen,et al.  Post Stroke Use of Selective Serotonin Reuptake Inhibitors and Clinical Outcome Among Patients With Ischemic Stroke: A Nationwide Propensity Score–matched Follow-up Study , 2013, Stroke.

[73]  T. Bergmeijer,et al.  Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting , 2011, Heart.

[74]  E. Trabetti,et al.  Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. , 2011, Journal of the American College of Cardiology.

[75]  B. Thombs,et al.  Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. , 2007, The American journal of medicine.

[76]  P. Souverein,et al.  Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C19*2 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention , 2011, Journal of thrombosis and haemostasis : JTH.

[77]  A. Erbay,et al.  Safety of Clopidogrel in Older Patients , 2011, Drugs & aging.

[78]  E. Trabetti,et al.  Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. , 2005, Thrombosis research.

[79]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[80]  R. Carney,et al.  Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. , 2005, Archives of general psychiatry.

[81]  R. Brugada,et al.  Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel , 2011, Heart.

[82]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[83]  A. Tonkin,et al.  High Platelet Reactivity and Antiplatelet Therapy Resistance , 2012, Seminars in Thrombosis & Hemostasis.

[84]  R. Desnick,et al.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. , 2010, Pharmacogenomics.

[85]  R. Desnick,et al.  Multi-ethnic Distribution of Clinically Relevant CYP2C Genotypes and Haplotypes , 2012, The Pharmacogenomics Journal.

[86]  K. Bestehorn,et al.  Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[87]  G. Montalescot,et al.  High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). , 2011, JACC. Cardiovascular interventions.

[88]  R. Kim,et al.  Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. , 2012, European heart journal.

[89]  D. Whellan,et al.  Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. , 2009, The American journal of cardiology.

[90]  N. Schork,et al.  Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. , 2012, Journal of the American College of Cardiology.

[91]  L Zhang,et al.  The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.

[92]  Christopher M O'Connor,et al.  Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy , 2003, Circulation.

[93]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[94]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[95]  A. Siegbahn,et al.  Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. , 2007, European heart journal.

[96]  N. Farid,et al.  Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel , 2009, Drug Metabolism and Disposition.

[97]  Cytochrome 2 C 19 * 17 Allelic Variant , Platelet Aggregation , Bleeding Events , and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2011 .

[98]  S. Hokimoto,et al.  Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. , 2014, Thrombosis research.

[99]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[100]  P. Morange,et al.  Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. , 2009, The American journal of cardiology.

[101]  H. Hemingway,et al.  Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD) , 2011, European heart journal.

[102]  L. Wallentin,et al.  New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis , 2013, European heart journal.

[103]  A. Kastrati,et al.  P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate‐induced platelet activation and aggregation after administration of a single high dose of clopidogrel , 2006, Journal of thrombosis and haemostasis : JTH.

[104]  P. Morange,et al.  Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. , 2007, Thrombosis research.

[105]  Deepak L. Bhatt,et al.  Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review , 2012, Heart.

[106]  K. Mahaffey,et al.  Clopidogrel and PPI Interaction: Clinically Relevant or Not? , 2012, Current Cardiology Reports.

[107]  Bin Jiang,et al.  The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease , 2014, Pharmacogenetics and genomics.

[108]  Bangshun He,et al.  CES1A −816C as a Genetic Marker to Predict Greater Platelet Clopidogrel Response in Patients with Percutaneous Coronary Intervention , 2014, Journal of cardiovascular pharmacology.

[109]  E. Topol,et al.  Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. , 2007, The American journal of cardiology.

[110]  Samin K. Sharma,et al.  Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity , 2013, Thrombosis and Haemostasis.

[111]  P. Kirchhof,et al.  Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a , 2010, European heart journal.

[112]  R. Storey,et al.  Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention , 2004, Platelets.

[113]  J. Hulot,et al.  Effect of an increased clopidogrel maintenance dose or lansoprazole co‐administration on the antiplatelet response to clopidogrel in CYP2C19‐genotyped healthy subjects , 2010, Journal of thrombosis and haemostasis : JTH.

[114]  P. Hjemdahl,et al.  Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co‐treatment , 2009, Journal of internal medicine.

[115]  E. Spina,et al.  Metabolic drug interactions with new psychotropic agents , 2003, Fundamental & clinical pharmacology.

[116]  P. Froguel,et al.  Regulation of carboxylesterase 1 (CES1) in human adipose tissue , 2009, Biochemical and biophysical research communications.

[117]  Deepak L. Bhatt,et al.  Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). , 2009, The American journal of cardiology.

[118]  Deepak L. Bhatt,et al.  Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. , 2013, Journal of the American College of Cardiology.

[119]  Hae-Young Lee,et al.  Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention , 2012, Heart.

[120]  W. Leng,et al.  Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease? , 2013, Thrombosis research.

[121]  L. Neyses,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[122]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[123]  D. Roden,et al.  Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record , 2012, Clinical pharmacology and therapeutics.

[124]  B. Jilma,et al.  Calcium channel blockers reduce the antiplatelet effect of clopidogrel , 2008, Journal of the American College of Cardiology.

[125]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[126]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[127]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[128]  E. Trabetti,et al.  PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[129]  G. Maurer,et al.  Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study , 2012, Journal of thrombosis and haemostasis : JTH.

[130]  E. Topol,et al.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. , 2008, JAMA.

[131]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[132]  A. Shuldiner,et al.  The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. , 2011, American heart journal.

[133]  M. Rubenfire,et al.  The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity , 2011, Journal of cardiovascular pharmacology.

[134]  Z. Wang,et al.  Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. , 2011, International journal of cardiology.

[135]  F. Neumann,et al.  Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement , 2007, Thrombosis and Haemostasis.

[136]  A. Michelson,et al.  Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH , 2009, Journal of thrombosis and haemostasis : JTH.

[137]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[138]  L. Bonello,et al.  High on treatment platelet reactivity. , 2012, Heart, lung & circulation.

[139]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[140]  P. Morange,et al.  Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. , 2010, Thrombosis research.

[141]  C. O'connor,et al.  Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study , 2004 .

[142]  J. Necciari,et al.  Pharmacokinetics of clopidogrel. , 1999, Seminars in thrombosis and hemostasis.

[143]  F. Leebeek,et al.  Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions , 2009, Circulation. Cardiovascular genetics.

[144]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[145]  R. Horenstein,et al.  A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[146]  M. Zwahlen,et al.  A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents , 2010, Thrombosis and Haemostasis.

[147]  A. Kastrati,et al.  No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. , 2011, European heart journal.

[148]  E. Mahmud,et al.  Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. , 2008, Journal of the American College of Cardiology.

[149]  Ronald D Lee,et al.  A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. , 2012, Journal of the American College of Cardiology.

[150]  J. Craig,et al.  Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[151]  J. Dery,et al.  Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation , 2013, Heart.

[152]  Bill G Felkey,et al.  Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. , 2003, Journal of the American Pharmacists Association : JAPhA.

[153]  Ai-Ming Yu,et al.  Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models , 2011, Drug metabolism reviews.

[154]  T. Furuta,et al.  Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. , 2010, British journal of clinical pharmacology.

[155]  M. Wiese,et al.  Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics , 2013, Clinical pharmacology and therapeutics.

[156]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[157]  O. Morel,et al.  Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. , 2011, Journal of the American College of Cardiology.

[158]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[159]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[160]  H. Katus,et al.  Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. , 2009, International journal of cardiology.

[161]  Deepak L. Bhatt,et al.  The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. , 2008, European heart journal.

[162]  K. Winters,et al.  Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel , 2008, Journal of clinical pharmacology.

[163]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[164]  M. Silkey,et al.  Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients , 2010, European Journal of Clinical Pharmacology.

[165]  C. Reid,et al.  Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. , 2010, JACC: Cardiovascular Interventions.

[166]  J. O’Connell,et al.  The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response , 2013, Pharmacogenetics and genomics.

[167]  B. Horne,et al.  Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes , 2013, Thrombosis and Haemostasis.

[168]  Christopher W. Good,et al.  Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial , 2012, Circulation. Cardiovascular interventions.

[169]  C. Macaya,et al.  Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.

[170]  E. Trabetti,et al.  Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[171]  C. Knibbe,et al.  Impact of Obesity on Drug Metabolism and Elimination in Adults and Children , 2012, Clinical Pharmacokinetics.

[172]  A. Kastrati,et al.  Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. , 2011, American heart journal.

[173]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[174]  Pier Franco Pignatti,et al.  Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease , 2007, BMC Medical Genetics.

[175]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[176]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[177]  C. Labos,et al.  Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction , 2011, Canadian Medical Association Journal.

[178]  R. Desnick,et al.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness , 2011, The Pharmacogenomics Journal.

[179]  T. Nolin,et al.  Thienopyridine efficacy and cigarette smoking status. , 2013, American heart journal.

[180]  A. de Boer,et al.  CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. , 2010, European heart journal.

[181]  N. Plant,et al.  The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[182]  S. James.  Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice. , 2009, AACN advanced critical care.

[183]  C. Hirschhäuser,et al.  Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.

[184]  Deepak L. Bhatt,et al.  Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.

[185]  Ya‐Ling Han,et al.  Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. , 2013, Chinese medical journal.

[186]  Jiyan Chen,et al.  Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients , 2013, European Journal of Clinical Pharmacology.

[187]  Mitsuaki Suzuki,et al.  Depot-specific expression of lipolytic genes in human adipose tissues--association among CES1 expression, triglyceride lipase activity and adiposity. , 2011, Journal of atherosclerosis and thrombosis.

[188]  H. Yamazaki,et al.  Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions , 2000, European Journal of Clinical Pharmacology.

[189]  M. Niemi,et al.  Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel , 2014, Clinical pharmacology and therapeutics.

[190]  S. Scott,et al.  CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients , 2011, Circulation. Cardiovascular interventions.

[191]  O. Pelkonen,et al.  Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation , 2005, Clinical pharmacology and therapeutics.

[192]  X Yu,et al.  J.Chromatogr., B: Anal. Technol. Biomed. Life Sci. , 2004 .

[193]  E. Minar,et al.  Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease , 2005, Stroke.

[194]  K. Huber,et al.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[195]  S. Steinhubl,et al.  Platelet function monitoring in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[196]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[197]  Z. Motovska,et al.  Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. , 2012, The American journal of cardiology.

[198]  Zhongyan Li,et al.  Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel , 2003, Circulation.

[199]  B. Giusti,et al.  Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status , 2014, Journal of Thrombosis and Thrombolysis.

[200]  A. de Boer,et al.  Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients , 2011, Platelets.

[201]  A. Siegbahn,et al.  Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. , 2008, Journal of the American College of Cardiology.